×
Enjoying ad-free content?
Since July 1, 2024, we have disabled all ads to improve your reading experience.
This commitment costs us $10,000 a month. Your support can help us fill the gap.
Support us
Our journalism is banned in Russia. We need your help to keep providing you with the truth.

Pharmstandard Sales Up 84%

Drug maker Pharmstandard said Thursday its third-quarter sales soared 84 percent, year-on-year, boosted by an early state tender for anti-cancer drugs.

Sales totaled 14.7 billion rubles, versus 8 billion rubles in the same period last year, the company said in a statement.

It said sales of Johnson & Johnson's anti-cancer drug Velcade totaled 4.8 billion rubles, accounting for one-third of total revenue, after the government shifted its tender to the third quarter from the fourth quarter.

As a result, total sales of third-party products soared 308 percent to stand at 8.1 billion rubles, while sales of the company's own drugs were up 8.3 percent to 6.2 billion rubles.

(Reuters)

Related articles:

… we have a small favor to ask. As you may have heard, The Moscow Times, an independent news source for over 30 years, has been unjustly branded as a "foreign agent" by the Russian government. This blatant attempt to silence our voice is a direct assault on the integrity of journalism and the values we hold dear.

We, the journalists of The Moscow Times, refuse to be silenced. Our commitment to providing accurate and unbiased reporting on Russia remains unshaken. But we need your help to continue our critical mission.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and you can be confident that you're making a significant impact every month by supporting open, independent journalism. Thank you.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more